Get the Stockscreener App
0.77
5.48%
0.04
Neurosense Therapeutics Ltd stock is traded at $0.77, with a volume of 142.82K.
It is up +5.48% in the last 24 hours and down -12.49% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.73
Open:
$0.71
24h Volume:
142.82K
Relative Volume:
0.62
Market Cap:
$25.72M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.318
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
-0.58%
1M Performance:
-12.49%
6M Performance:
-34.75%
1Y Performance:
-30.00%
1-Day Range:
$0.71
$0.7838
1-Week Range:
$0.63
$0.815
52-Week Range:
$0.63
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.77 | 25.72M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Buy” Rating from D. Boral Capital - Defense World
NeuroSense Therapeutics (NRSN): Analyst Reaffirms 'Buy' Rating | - GuruFocus
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - Finviz
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens - TipRanks
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) - Stock Titan
NeuroSense delays Canada meeting to add data as Alzheimer’s results near - Stock Titan
Chart Watch: Is NeuroSense Therapeutics Ltd in a consolidation phase2026 Analyst Calls & Verified Technical Trade Signals - baoquankhu1.vn
NeuroSense Therapeutics Ltd.: Fundamental Analysis and Financial Ratings | H1Z | IL0011809592 - marketscreener.com
NeuroSense (NRSN) director Pellizzari details option and share holdings - Stock Titan
NeuroSense Therapeutics (NRSN) CMO details option and warrant holdings - Stock Titan
NeuroSense (NRSN) director details options and restricted share holdings - Stock Titan
NeuroSense (NRSN) GM Hagit Binder details share, option and RSU holdings - Stock Titan
/C O R R E C T I O N -- NeuroSense/ - PR Newswire
Bull Bear: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingStop Loss & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PR Newswire
Neurosense Therapeutics Ltd - Reuters
NeuroSense Therapeutics (NRSNW) Projected to Post Quarterly Earnings on Wednesday - Defense World
Director at NeuroSense (NASDAQ: NRSN) discloses equity awards and vesting - Stock Titan
EPS Watch: Whats the fair value of NeuroSense Therapeutics Ltd stock2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is United Therapeutics Corporation gaining market share2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Opening: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Breakout Watch: Will NeuroSense Therapeutics Ltd Equity Warrant benefit from green energy policiesTrend Reversal & Consistent Return Investment Signals - baoquankhu1.vn
FOMO Trade: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2026 Top Gainers & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-03-17 06:01:38 - baoquankhu1.vn
NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology - TipRanks
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PR Newswire
Tangible book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50 - Defense World
Operating cash flow per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
NeuroSense Shareholders Approve Increase in Registered Share Capital - The Globe and Mail
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
NeuroSense "PrimeC" Market size expansion of Several Folds by 2034 - openPR.com
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - GuruFocus
Roth/MKM initiates NeuroSense stock with buy on ALS drug potential - Investing.com Nigeria
Roth/MKM initiates NeuroSense stock with buy on ALS drug potential By Investing.com - Investing.com South Africa
Neurosense Therapeutics Ltd. Presents Long-Term Survival Data for Primec in Amyotrophic Lateral Sclerosis - marketscreener.com
Analysis Recap: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leadersMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Long-Term Data From PARADIGM Trial Suggest Survival Benefit With PrimeC in ALS - NeurologyLive
Buy Signal: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectationsSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Will NeuroSense Therapeutics Ltd. stock continue upward momentumJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - Naître et grandir
Insider Sell: What are the risks of holding NeuroSense Therapeutics Ltd Equity WarrantJuly 2025 Update & Capital Efficiency Focused Ideas - baoquankhu1.vn
Revenue Check: Whats the fair value of NeuroSense Therapeutics Ltd stockRisk Management & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Published on: 2026-03-06 17:33:43 - baoquankhu1.vn
NRSN SEC FilingsNeurosense Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Revenue Check: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2025 Technical Patterns & Verified Momentum Stock Ideas - baoquankhu1.vn
IANS - IANS
Book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
Buyback Watch: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right now2025 Market WrapUp & Verified Momentum Watchlists - baoquankhu1.vn
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):